NASDAQ: ALBO |
| Healthcare / Biotechnology / USA |
21.16 | -1.73 | -7.56% | Vol 924.62K | 1Y Perf -25.24% |
May 18th, 2022 16:00 DELAYED |
BID | 18.39 | ASK | 22.10 | ||
Open | 22.43 | Previous Close | 22.89 | ||
Pre-Market | - | After-Market | 21.14 | ||
- - | -0.02 -0.09% |
Target Price | 73.75 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 248.54 | Finscreener Ranking | ★★★★★ 62.62 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ 56.98 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★+ 66.09 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 4.90 | Earnings Rating | Sell | |
Market Cap | 414.02M | Earnings Date | 16th May 2022 | |
Alpha | 0.01 | Standard Deviation | 0.14 | |
Beta | 0.95 |
Today's Price Range 20.5422.43 | 52W Range 20.3037.86 | 5 Year PE Ratio Range -6.00-1.60 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -16.58% | ||
1 Month | -33.86% | ||
3 Months | -29.46% | ||
6 Months | -8.37% | ||
1 Year | -25.24% | ||
3 Years | -36.38% | ||
5 Years | 6.32% | ||
10 Years | -70.65% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -35.70 | |||
ROE last 12 Months | -19.77 | |||
ROA (5Y Avg) | -13.93 | |||
ROA last 12 Months | -11.98 | |||
ROC (5Y Avg) | -43.95 | |||
ROC last 12 Months | -10.68 | |||
Return on invested Capital Q | -4.08 | |||
Return on invested Capital Y | -4.08 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 23.60 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-15.10 | ||||
3.12 | ||||
14.21 | ||||
- | ||||
-7.50 | ||||
-5.60 | ||||
3.46 | ||||
8.97 | ||||
309.76M | ||||
Forward PE | -7.00 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.50 | ||||
5.90 | ||||
0.05 | ||||
0.06 | ||||
-1.40 | ||||
Leverage Ratio | 1.80 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
96.70 | ||||
-49.50 | ||||
-48.90 | ||||
-484 511.00 | ||||
21.67 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
38.61M | ||||
1.97 | ||||
139.27 | ||||
157.90 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | -2.02 | -2.19 | -8.42 |
Q04 2021 | -1.27 | -0.57 | 55.12 |
Q03 2021 | 0.54 | -1.26 | -333.33 |
Q02 2021 | -1.92 | -1.90 | 1.04 |
Q01 2021 | -1.72 | -2.29 | -33.14 |
Q04 2020 | -1.90 | -1.30 | 31.58 |
Q03 2020 | -1.48 | -1.96 | -32.43 |
Q02 2020 | -1.65 | -1.38 | 16.36 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
3/2022 QR | -2.02 | -19.53 | Negative |
6/2022 QR | -1.93 | -26.97 | Negative |
12/2022 FY | -7.11 | -11.09 | Negative |
12/2023 FY | -4.00 | -39.86 | Negative |
Next Report Date | - |
Estimated EPS Next Report | -2.02 |
Estimates Count | 4 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 924.62K |
Shares Outstanding | 19.57K |
Shares Float | 14.71M |
Trades Count | 11.98K |
Dollar Volume | 19.57M |
Avg. Volume | 401.51K |
Avg. Weekly Volume | 607.64K |
Avg. Monthly Volume | 293.67K |
Avg. Quarterly Volume | 303.24K |
Albireo Pharma Inc. (NASDAQ: ALBO) stock closed at 22.89 per share at the end of the most recent trading day (a -18.37% change compared to the prior day closing price) with a volume of 2.04M shares and market capitalization of 414.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 90 people. Albireo Pharma Inc. CEO is Ronald H.W. Cooper.
The one-year performance of Albireo Pharma Inc. stock is -25.24%, while year-to-date (YTD) performance is -1.72%. ALBO stock has a five-year performance of 6.32%. Its 52-week range is between 20.3 and 37.86, which gives ALBO stock a 52-week price range ratio of 4.90%
Albireo Pharma Inc. currently has a PE ratio of -15.10, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 14.21, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -11.98%, a ROC of -10.68% and a ROE of -19.77%. The company’s profit margin is 21.67%, its EBITDA margin is -48.90%, and its revenue ttm is $38.61 Million , which makes it $1.97 revenue per share.
Of the last four earnings reports from Albireo Pharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-2.02 for the next earnings report. Albireo Pharma Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Albireo Pharma Inc. is Strong Buy (1), with a target price of $73.75, which is +248.54% compared to the current price. The earnings rating for Albireo Pharma Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Albireo Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Albireo Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.60, ATR14 : 2.31, CCI20 : -253.46, Chaikin Money Flow : -0.21, MACD : -1.69, Money Flow Index : 26.78, ROC : -28.06, RSI : 26.08, STOCH (14,3) : 16.42, STOCH RSI : 0.00, UO : 34.76, Williams %R : -83.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Albireo Pharma Inc. in the last 12-months were: Jan P. Mattsson (Sold 1 008 shares of value $26 690 ), Jason G. Duncan (Option Excercise at a value of $396 365), Jason G. Duncan (Sold 19 268 shares of value $674 998 ), Martha Carter (Sold 526 shares of value $13 762 ), Michelle Graham (Sold 521 shares of value $13 725 ), Pamela Stephenson (Sold 2 369 shares of value $70 357 ), Patrick Taylor Horn (Sold 185 shares of value $5 811 ), Ronald H.W. Cooper (Option Excercise at a value of $229 762), Ronald H.W. Cooper (Sold 4 591 shares of value $121 697 ), Simon Nicolas Reade Harford (Sold 917 shares of value $26 297 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.
CEO: Ronald H.W. Cooper
Telephone: +1 857 254-5555
Address: 10 Post Office Square, South Boston 02109, MA, US
Number of employees: 90
Wed, 13 Apr 2022 14:55 GMT Wedbush Believes Albireo Pharma (ALBO) Still Has Room to Grow
- TipRanks. All rights reserved.Tue, 29 Mar 2022 15:15 GMT Albireo Pharma (ALBO) Gets a Buy Rating from H.C. Wainwright
- TipRanks. All rights reserved.Thu, 03 Mar 2022 10:16 GMT Albireo Pharma (ALBO) Gets a Buy Rating from Robert W. Baird
- TipRanks. All rights reserved.Wed, 02 Mar 2022 16:05 GMT Albireo Pharma (ALBO) Received its Third Buy in a Row
- TipRanks. All rights reserved.Thu, 06 Jan 2022 11:25 GMT Analysts Top Healthcare Picks: Albireo Pharma (ALBO), Cogent Biosciences (COGT)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.